



D2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/00, 39/116, 39/02, C07K 16/00, G01N 33/53, 33/554		A1	(11) International Publication Number: WO 99/49889 (43) International Publication Date: 7 October 1999 (07.10.99)
(21) International Application Number: PCT/US99/07056 (22) International Filing Date: 31 March 1999 (31.03.99)		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 60/080,166 31 March 1998 (31.03.98) US 09/277,599 26 March 1999 (26.03.99) US		Published <i>With international search report.</i>	
(71) Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF AGRICULTURE [US/US]; 1400 Independent Avenue S.W., Washington, DC 20250-0302 (US).			
(72) Inventors: MANDRELL, Robert, E.; 546 Este Madera Drive, Sonoma, CA 95476 (US). BATES, Anna, H.; 3152 Stanley Boulevard, Lafayette, CA 94549 (US). BRANDON, David, L.; 1639 Lincoln Street, Berkeley, CA 94703 (US).			
(74) Agents: PENDORF, Stephan, A. et al.; Pendorf & Cutliff, P.O. Box 20445, Tampa, FL 33622-0445 (US).			
(54) Title: MONOCLONAL ANTIBODIES AGAINST CAMPYLOBACTER JEJUNI AND CAMPYLOBACTER COLI OUTER MEMBRANE ANTIGENS			
(57) Abstract			
<p>The present invention is directed to a method of producing monoclonal antibodies that are highly specific for (1) unique epitopes of <i>Campylobacter jejuni</i> (Cj) only and (2) epitopes conserved between <i>Campylobacter jejuni</i> and <i>Campylobacter coli</i> (Cc) outer membranes; to specific monoclonal antibodies made by the methods of the instant invention; and uses thereof. The invention is drawn further to immunogens comprising the outer membrane complexes of Cj and Cc.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MONOCLONAL ANTIBODIES AGAINST CAMPYLOBACTER JEJUNI AND
CAMPYLOBACTER COLI OUTER MEMBRANE ANTIGENS

FIELD OF THE INVENTION

The present invention relates generally to a method of preparing an immunogen comprising outer membranes from *Campylobacter jejuni* (hereafter designated Cj) and *Campylobacter coli* (hereafter designated Cc), inoculating animals with the immunogen, and detecting the desired hybridoma-producing antibodies; and to a composition comprising the immunogen. The invention is drawn further to hybridoma cell lines developed by this method to produce (1) monoclonal antibodies specific to Cj only and (2) monoclonal antibodies that recognize both Cj and Cc exclusively, and uses thereof.

BACKGROUND OF THE INVENTION

Campylobacters cause more human gastroenteritis than any other food-borne pathogen. *Campylobacter enteritis* is caused by two closely related species, Cj and Cc, but Cj is responsible for greater than 98% of human disease and produces more severe symptoms. Cj, has been further subdivided into Cj subspecies *jejuni* (Cjj) and Cj subspecies *doylei* (Cjd). (In the remainder of this application, the term Cjj will be used to designate *C. jejuni* subspecies *jejuni* and Cjd to designate *C. jejuni* subspecies *doylei*. The term Cj (*Campylobacter jejuni*) will be used to describe both *C. jejuni* subspecies *jejuni* and *C. jejuni* subspecies *doylei* collectively.) Cjj and Cjd are closely related; however, Cjj is the predominant subspecies causing human illness and isolated from food sources. Cj and Cc cause acute diarrhea in humans with associated enteritis, particularly in developing countries. These infections are prevalent in infants under 1 year in age and rank as the third most common cause of acute diarrhea after Rotavirus and enterotoxigenic *Escherichia coli*. The various clinical patterns of disease suggest that *Campylobacter* spp. and, more specifically, Cj strains are diverse and may possess more than one type of virulence factor. In addition, Cj, unlike Cc, are more often

associated with symptomatic infections and with bloody diarrhea.

Since *Campylobacter enteritis* is a considerable world health problem contributing to morbidity in developed countries and to high mortality rates in children in developing countries, it is of clinical importance to develop a specific and rapid diagnostic assay to identify pathogenic *Campylobacter* in the stool of enteritis patients. The available culture methods for detecting the organism generally are extremely time consuming and costly. Several studies have reported production of anti-*Campylobacter* Mabs and their use in immunoassays to detect *Campylobacter* infection (Chaiyaroj et al., 1995).

Campylobacter was not recognized as a human pathogen until the mid 1970's. Previously, the principal food-borne pathogen of concern had been *Salmonella* spp. Since the 1970s, the food industry and the regulatory agencies have become aware of the importance of other food-borne pathogens, such as *Yersinia enterocolitica*, *Escherichia coli* O157:H7, and *Listeria monocytogenes*. Very recently, *Cj* has become recognized as the most frequent cause of gastroenteritis in the U.S. and has been observed as the most common pathogen associated with Guillain-Barre syndrome in humans. It is estimated that about 1 in 1,000 *Campylobacter* infections results in this serious illness (Nachamkin et al., 1992).

Campylobacter is very prevalent in poultry (Madden et al., 1998) and contaminates milk (Docherty et al., 1996). Hazard analysis critical control point (HACCP) systems for poultry are being implemented internationally (Notermans et al., 1994), and beginning in 1997 in the U.S., large poultry processors have been required to meet performance standards for the frequency and amount of *Salmonella* in their product (Anonymous, 1996). It is anticipated that similar performance standards will be established for *Campylobacter* spp. as better culture and quantitative detection methods are developed. The development of rapid, reliable, and cost-effective methods for the detection of food-borne pathogens is crucial to accurately assess the safety of a food product, the effectiveness of new control measures to minimize pathogens in a production or processing

environment, and the basic biology and ecology of pathogens in the food environment.

Campylobacters are known to be widespread in the environment and contaminate soil and water (Stanley et al., 1998). Environmental monitoring requires detection methods that are field-based, portable, rapid, and capable of analyzing multiple samples. Biosensors that contain specific immobilized antibodies to capture a pathogen for subsequent detection by a laser light or other sensitive detection system are being developed (Zhou et al., 1998). The specificity, sensitivity, and affinity of the antibody in a biosensor are key factors for success.

The following U.S. patents are incorporated by reference.

U.S. Pat. No. 4,404,194 discloses a 90 kDa protein from *C. jejuni* that has immuno-suppressive activity.

U.S. Pat. No. 4,785,086 discloses a DNA probe for detecting *C. jejuni*.

U.S. Pat. No. 4,882,271, discloses a 300-700 kDa antigen from *Campylobacter pylori* and its use in various assays.

U.S. Pat. No. 4,942,126 discloses a method of identifying the presence of *Campylobacter* spp. in fecal specimens.

U.S. Pat. No. 5,200,344 discloses a method of identifying the presence of antibodies to *C. jejuni* or *C. coli* in test samples.

U.S. Pat. No. 5,374,531 discloses a method of analyzing particulate analytes, such as whole cells, in immunoassays.

U.S. Pat. No. 5,470,958 discloses an antigenic composition and antisera raised against a purified PEB1 antigen from *C. jejuni*.

U.S. Pat. Nos. 5,491,068 and 5,695,946 disclose a method of capturing specific bacterial cells with specific antibodies immobilized on magnetic beads.

U.S. Pat. No. 5,665,582 discloses a method for reversibly anchoring a biological material, such as a plastid, chromosome, nucleic acid, or protein to a solid support for use in an immunoassay.

U.S. Pat. No. 5,821,066 discloses a method of detecting, identifying, and quantifying respiring microorganisms in an immunoassay.

BRIEF SUMMARY OF THE INVENTION

The present invention provides for an immunogen comprising outer membrane complexes from multiple strains of *C. jejuni* and *C. coli*, the immunogen inducing an immune response in animals, such as mice, enhancing the production of hybridomas specific for *C. jejuni* and *C. coli* epitopes, wherein the immunogen induces a broad range of antibodies against many outer membrane molecules of *C. jejuni* and *C. coli*, but not against other gram-negative enteric bacteria or non-*jejuni/coli* *Campylobacter*.

Monoclonal antibodies of the present invention made by using such an immunogen are specific for epitopes expressed on *C. jejuni* and *C. coli*, wherein the monoclonal antibody binds the *C. jejuni* and *C. coli* porin protein or carbohydrate bound to porin protein, the porin comprising the 45kD and 35 kD monomeric forms and the trimeric form of the porin.

The invention also provides for monoclonal antibodies which bind specifically to a 43 kD protein expressed only on *C. jejuni* strains, or to carbohydrate bound to a 43 kD protein expressed only on *C. jejuni* strains.

The invention provides for a method of testing a sample for the presence of *C. jejuni* and/or *C. coli* comprising the steps of:

- (a) exposing a sample suspected of containing *C. jejuni* and/or *C. coli* to a MAb which specifically binds *C. jejuni* and *C. coli*;
- (b) detecting MAb-antigen binding, said binding being indicative of the presence of *C. jejuni* and/or *C. coli* in said sample; and
- (c) capturing *C. jejuni* or *C. coli* with MAb-conjugated-magnetic beads or MAb-conjugated-polystyrene beads or MAb conjugated or bound to a solid matrix, and detection of bound *C. jejuni* or *C. coli* with a method selected from: a second specific MAb, a PCR-specific assay, mass spectrometry (MALDI-

TOF), reported phage specific for *C. jejuni* or *C. coli*, optical sensing, or electronic sensing.

The invention also provides for a method of immunizing animals by:

- (a) preparing an immunogenic complex by isolating outer membrane complexes from at least two *Campylobacter* strains selected from at least one *C. jejuni* and at least one *C. coli*;
- (b) pooling in approximately equivalent concentrations of the *Campylobacter* outer membrane complexes;
- (c) immunizing animals intravenously; and
- (d) screening antisera for *Campylobacter* antibody production.

The invention provides further for a method of making a monoclonal antibody specific for epitopes expressed on the outer membranes of *C. jejuni* and *C. coli*, wherein the monoclonal antibody binds a *C. jejuni* and *C. coli* porin protein or a porin protein-carbohydrate complex, the method comprising:

- (a) preparing an immunogenic complex by isolating outer membrane complexes from at least two *Campylobacter* strains selected from the group consisting of *C. jejuni* and *C. coli*;
- (b) pooling in approximately equivalent concentrations of the *Campylobacter* outer membrane complexes;
- (c) immunizing animals intravenously;
- (d) screening antisera for *Campylobacter* antibody production;
- (e) fusing isolated spleen cells from animals positive for *Campylobacter* antibody production and myeloma cells;
- (f) isolating hybridomas making antibodies that bind *Campylobacter*; and
- (g) screening and identifying monoclonal antibodies that bind *Campylobacter*.

The present invention further provides for monoclonal antibodies made by such a method, wherein the MAb binds common epitopes of *C. jejuni* and *C. coli*.

The present invention is summarized further in that monoclonal antibodies specific for (1) unique epitopes of *C. jejuni* and (2) epitopes conserved between *C. jejuni* and *C. coli*

outer membranes are produced by hybridomas formed by the fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with a mixture of outer membrane complexes (OMC) isolated from eight LPS serotype strains and two poultry strains of *C. jejuni* and *C. coli*. The monoclonal antibody designated as C731 is characterized in that it reacts with a protein having a molecular weight of approximately 44 kilodaltons and a carbohydrate moiety. The monoclonal antibody designated as C740 is characterized in that it reacts with a protein having a molecular weight of approximately 43 to 44 kilodaltons and a carbohydrate moiety.

The present invention is further directed to a process for producing monoclonal antibodies against *Campylobacters* comprising propagating a hybridoma formed by fusing a cell capable of producing antibodies against (1) *C. jejuni* or (2) *C. jejuni* and *C. coli* with a myeloma cell and harvesting the antibodies produced by the hybridoma.

It is an object of the present invention to produce monoclonal antibodies that are highly specific for (1) specific or distinct epitopes of *C. jejuni* and (2) epitopes shared between *C. jejuni* and *C. coli* outer membranes.

Another object of the present invention is to develop tests using monoclonal antibodies to assay for *C. jejuni* and *C. coli* isolated in pure culture and in clinical, food, and water samples.

It is further an object of the present invention to develop immunoassays for the detection of *Campylobacter* in food and in clinical specimens.

Another object of the present invention is to develop a procedure to isolate *C. jejuni* and *C. coli* from foods or other samples and to determine the prevalence of the organisms in the samples.

It is another object of the present invention to detect a neo-epitope of the outer membrane of *C. jejuni*, the neo-epitope defined here as an antigenic epitope comprising a porin protein-carbohydrate complex, wherein the neo-epitope is specific for *C. jejuni* and does not cross-react with other *Campylobacters*.

Because of their high specificity, the monoclonal antibodies may be a useful reagent for the detection of *C. jejuni* and/or *C. coli* in foods, clinical specimens, or in situ localization of the bacteria. The antibodies of the present invention may be used further to monitor environmental and/or waste water or various facilities for *C. jejuni* and/or *C. coli* contamination. The testing procedure would include, for example, enzyme-linked immunoassays (ELISAs), immunomagnetic capture, radioimmune assays, biosensor assays and other immunoassays including, but not limited to microscopic methods.

The monoclonal antibodies of the present invention may be used singly or in combination, such as in a cocktail mixture, to detect specific *Campylobacter* species, as neutralizing antibodies, or in a composition comprising one or more antibodies to be used in administering passive immunity to humans, livestock, poultry, or other animals.

The antibodies may be used further in side-by-side assays to determine whether the samples react only with the antibodies specific for both *C. jejuni* and *C. coli* or whether they react only with the antibodies that are specific for *C. jejuni* alone.

Another object of the invention is to provide an immunogen comprising outer membrane complexes from multiple strains of *C. jejuni* used as a vaccine which induces high levels of specific antibodies directed against *C. jejuni* and which protects against *C. jejuni* infection in humans, livestock, poultry, or other animals.

An additional object of the invention is to provide an immunogen comprising outer membrane complexes from multiple strains of *C. jejuni* and *C. coli* used as a vaccine which induces high levels of specific antibodies directed against both *C. jejuni* and *C. coli* and which protects against *C. jejuni* and *C. coli* infection in humans, livestock, poultry, or other animals.

Other objects and advantages of the invention will be apparent from the following detailed description and figures setting forth the preferred embodiment of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 (A through F) shows the binding of MAbs in an ELISA to *Campylobacter* and other Gram-negative species of bacteria. A dilution of each of the MAbs was added to microtiter wells containing dried bacterial cells and the binding of MAb was detected with an alkaline phosphatase-conjugated goat anti-mouse IgG secondary antibody and substrate. MAbs were tested for binding to various strains of bacteria (X-axis) in an ELISA. The binding activity (OD_{405}) of a similar dilution of each antibody was determined (Y-axis). All MAbs were assayed initially with approximately 120 strains of bacteria. Figure 1A and Figure 1B: MAbs C731 and C740 were identified as specific for Cj and Cc, and Cj only, respectively. These two MAbs were tested with approximately 120 additional strains (mostly *Campylobacter*). MAb C731 binds predominantly to a 45 kD protein (Figure 2); MAb C740 binds predominantly to an approximately 44 kD protein. Figures 1C through 1F: The graphs representing other MAb binding results have been ordered from the top left to the bottom right based on their specificities for (a) all or most strains of both Cc and Cj, (b) all or most strains of Cj and many Cc, (c) most strains of Cj, (d) some strains of Cj and Cc, and (e) a few strains of Cj. The binding of biotinylated cholera toxin subunit b (CTb), which is specific for GM1 ganglioside, also is shown (bottom right graph). CTb bound to approximately 30% of the Cj strains tested. Cj has been shown to express a variety of ganglioside-like lipopolysaccharide (LPS) structures, including a GM1-like LPS [G. O. Aspinall, et al. *Biochem.* 33, 241 (1994), A. P. Moran, et al. *FEMS Microbiol. Lett.* 16, 105 (1996)].

Figure 2 (A and B) shows immunoblots of MAbs with outer membrane antigens. Molecules in outer membrane preparations (OM) of Cj or Cc were separated by SDS-PAGE on both a 7.5% and 15% gel, blotted to nitrocellulose, then tested with MAbs. Both heated (10 min, 100 C: "H") and non-heated samples were separated on the 7.5% gel (Figure 2A); only heated samples were separated on the 15% gel (Figure 2B). MAb binding was detected with an alkaline-phosphatase-conjugated goat anti-mouse Ig

antibody and substrate. MAbs were identified that recognize: (a) epitopes on molecules ranging in size from approximately 18 to 66 Mr; (b) heat stable (see C740, C797, C805) and unstable (see C753, C779, C783, C791) epitopes; (c) heat modifiable proteins, and (d) molecules migrating at multiple Mr, especially those in unheated samples (see C731, C740, C736, C775, C779, C805, C807). MAb C731 recognizes the major outer membrane protein (MOMP, porin) of both Cj and Cc (anti-Cj/Cc) (see Figure 4). The Cj porin has been described previously as a 45 kD protein that migrates in SDS-PAGE gels both as 45 and 35 kD monomers (heat modifiable) [W. Schroder, and I. Moser, *FEMS Microbiol Lett.* 150, 141 (1997), J.-M. Bolla, et al., *J Bacteriol.* 177, 4266 (1995)].

Figure 3 shows an immunoblot demonstrating the binding of MAbs C731, C740, and C753 to proteins of two Cj strains and a Cc strain. Heated samples were run in a 10% gel.

Figure 4 shows an immunoblot of MAb C740 binding strongly to OMC of 5 Cj strains, but not to any of the OMC of 4 Cc strains. The MAb binds to the 43-44 kD protein best, but also binds to many other proteins of higher and lower Mr and present at lower concentrations.

Figure 5 (A and B) shows a nitrocellulose blot of Cj and Cc OMC stained for carbohydrate. Molecules in Cj OMC were separated by SDS-PAGE on a 10% gel, blotted to nitrocellulose, then probed with MAbs and lectins. Figure 5A (Cc strain RM1051 OMC): lane 1: *Limax flavus* agglutinin; lane 2: elderberry bark lectin; lane 3: *Maackia amurensis* agglutinin; lane 4: DIG Glycan stain (experiment 2); lane 5: DIG Glycan stain (experiment 2); lane 6: DIG Glycan stain (experiment 1); lane 7: DIG Glycan stain (experiment 1); lane 8: MAb C731 anti-porin; and lane 9: India ink stain. Figure 5B (Cjj strain RM1222 OMC): lane 1: *Limax flavus* agglutinin; lane 2: elderberry bark lectin; lane 3: *Maackia amurensis* agglutinin; lane 4: DIG Glycan stain (experiment 2); lane 5: DIG Glycan stain (experiment 1); lane 6: DIG Glycan stain (experiment 1); lane 7: MAb C740 anti-porin; and lane 8: India ink stain. The same Cj and Cc OMCs were tested also for the presence of

carbohydrate using the DIG Glycan Stain (Boehringer-Mannheim) and lectins and were positive for carbohydrate. An India Ink stain of the blot resulted in a "negative stain" of the porin, further indicating the presence of carbohydrate on porin.

Figure 6 shows a two-dimensional gel/immunoblot of MAb C740 binding to molecules of Cj OMC. A sample of Cj strain RM1222 OMC was run in an isoelectric focusing gel, then in a second dimension by SDS-PAGE. Molecules in the SDS-PAGE gel were electroblotted to nitrocellulose and tested for binding of MAb C740. The molecules recognized by C740 ran in a broad region at pH 4.

Figure 7 shows the binding of MAb C740 to colonies of strain Cj strain RM1221. Colonies on an agar plate were transferred to nitrocellulose, dried, then incubated with a dilution of MAb C740. Binding of the MAb was detected with an alkaline phosphatase-conjugated goat anti-mouse IgG and 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium or bromochloroindolyl phosphate (BCIP/NBT) substrate.

Figure 8 (A and B) shows the binding of fluorophore-conjugated MAbs C731 and C740 to Cj. The purified MAbs C731 and C740 were conjugated with fluorophores with excitations at 488 nm and 568 nm, respectively.

Figure 9 shows Cj cells present on chicken skin. Retail chicken skin was incubated with MAb C740, then a fluorescent secondary antibody. MAb binding was observed by confocal microscopy.

Figure 10 (A through D) shows the qualitative results of binding of MAbs by ELISA to each of the bacteria represented in the immunogen for Fusion 1. The bacteria used as antigen in the ELISA are listed as *Campylobacter jejuni* (Cj) or *Campylobacter coli* (Cc) and the Penner LPS serotype strains (O:1, O:2, O:3, O:4, O:19, O:23, O:30, O:36) are designated.

Figure 11 (A through I) shows the qualitative results of binding of MAbs by ELISA to each of the bacteria represented in the immunogen for Fusion 2. The antigens tested and LPS serotype designation are the same as for Figure 10.

DETAILED DESCRIPTION OF THE INVENTION

Before the present antibodies, assays, and methods for producing and using such are disclosed and described, it is to be understood that this invention is not limited to particular antibodies, assays, or methods, as they may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications and patents mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which they are cited.

MAb C731, which recognizes both *C. jejuni* and *C. coli*, was recloned and renamed C818. MAb C818 was deposited under the Budapest Treaty with American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 on February 23, 1999, verified to be viable on March 12, 1999, and has been accorded ATCC Designation HB-12651.

MAb C740, which specifically recognizes only *C. jejuni*, was recloned and renamed C825. MAb C825 was deposited under the Budapest Treaty with American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 on February 23, 1999, verified to be viable on March 12, 1999, and has been accorded ATCC Designation HB-12652.

Permanence of the deposits and ready accessibility thereto is provided in accordance with U.S. patent law, the Budapest Treaty, and other applicable laws and regulations. The deposits will be accessible to the public on and after the date of issuance of any U.S. patent arising from the present patent application, which refers to the deposits. All restrictions upon availability of the deposited monoclonal antibodies will be

irrevocably removed upon granting of any U.S. patent arising from the present application.

The present invention provides for an immunogen comprising outer membrane complex from multiple strains of *C. jejuni* and *C. coli*, the immunogen inducing an immune response in animals, mice in particular, enhancing the production of hybridomas specific for *C. jejuni* and *C. coli* epitopes, wherein the immunogen induces a broad range of antibodies against many outer membrane molecules of *C. jejuni* and *C. coli*, but not against other gram-negative enteric bacteria or non-*jejuni/coli* *Campylobacter*. The immunogen may comprise outer membrane complexes from two or more strains of *C. jejuni* and *C. coli*, preferably from two to ten strains of *C. jejuni* and *C. coli*, more preferably from five to ten strains, in any combination thereof. The immunogen may be made be from outer membrane complexes from two, three, four, five, six, seven, eight, nine, ten, or more strains of *C. jejuni* and *C. coli*, in any combination. The immunogen may further comprise outer membrane complexes from one or more environmental *C. jejuni* and/or *C. coli* strains isolated from commercially available chickens from the supermarket. In the most preferred embodiment, the immunogen comprises outer membrane complexes from seven strains of *C. jejuni* and one strain of *C. coli* and two environmental *C. jejuni* and/or *C. coli* strains isolated from commercially available chickens from the supermarket.

Monoclonal antibodies of the present invention made by using such an immunogen are specific for epitopes expressed on *C. jejuni* and *C. coli*, wherein said monoclonal antibody binds the *C. jejuni* and *C. coli* porin protein or carbohydrate bound to porin protein, the porin comprising the 45kD and 35 kD monomeric forms and the trimeric form of the porin.

The invention also provides for monoclonal antibodies which bind specifically to a 43 kD protein expressed only on *C. jejuni* strains, or to carbohydrate bound to a 43 kD protein expressed only on *C. jejuni* strains.

The invention provides for a method of testing a sample for the presence of *C. jejuni* and/or *C. coli* comprising the steps of:

(a) exposing a sample suspected of containing *C. jejuni* and/or *C. coli* to MAb which specifically binds *C. jejuni* and *C. coli*;

(b) detecting MAb-antigen binding, said binding being indicative of the presence of *C. jejuni* and/or *C. coli* in said sample; and

(c) capturing *C. jejuni* or *C. coli* with MAb-conjugated-magnetic beads or MAb-conjugated-polystyrene beads or MAb conjugated or bound to a solid matrix, and detection of bound *C. jejuni* or *C. coli* with: a second specific MAb, a PCR-specific assay, mass spectrometry (MALDI-TOF), reporter phage specific for *C. jejuni* or *C. coli*, optical sensing, or electronic sensing.

The method of testing is described further wherein the sample is selected from the group consisting of poultry, swine and bovine carcasses, tissues and manure; animal production (farm) or processing water and equipment; biofilms on surfaces of animal carcasses, cells, tissues, production equipment or processing equipment; clinical samples (for example, feces or blood); fruit and vegetables; and fruit and vegetable irrigation and processing water.

The invention also provides for a method of immunizing animals by:

(a) preparing an immunogenic complex by isolating outer membrane complexes from at least two *Campylobacter* strains selected from the group consisting of *C. jejuni* and *C. coli*;

(b) pooling in approximately equivalent concentrations of the *Campylobacter* outer membrane complexes;

(c) immunizing animals intravenously; and

(d) screening antisera for *Campylobacter* antibody production.

The invention also provides for a method of making monoclonal antibodies specific for epitopes expressed on the outer membranes of *C. jejuni* and *C. coli*, wherein said monoclonal antibody binds a *C. jejuni* and *C. coli* porin protein or a porin protein-carbohydrate complex, the method comprising:

(a) preparing an immunogenic complex by isolating outer

membrane complexes from at least two *Campylobacter* strains selected from *C. jejuni* or *C. coli*;

(b) pooling in approximately equivalent concentrations of the *Campylobacter* outer membrane complexes;

(c) immunizing animals intravenously;

(d) screening antisera for *Campylobacter* antibody production;

(e) fusing isolated spleen cells from animals positive for *Campylobacter* antibody production and myeloma cells;

(f) isolating hybridomas making antibodies that bind *Campylobacter*; and

(g) screening and identifying monoclonal antibodies that bind *Campylobacter*.

The method further provides an immunogen, which additionally comprises *Campylobacter* strains isolated in an approximately 1 M NaCl wash of fresh chicken epidermis.

The present invention also provides for monoclonal antibodies, made by such a method, that bind only *Campylobacter jejuni*.

The present invention further provides for monoclonal antibodies, made by such a method, that bind common epitopes of *C. jejuni* and *C. coli*.

More specifically, the present invention is drawn to a monoclonal antibody made by such a method and is designated as C731, recloned and renamed as C818, and deposited as ATCC HB-12651.

The invention also provides for a monoclonal antibody made by such a method and is designated as C740, recloned and renamed as C825, and deposited as ATCC HB-12652.

The present invention provides for the production of monoclonal antibodies that are highly specific for (1) specific or unique epitopes of *C. jejuni* and (2) epitopes shared between *C. jejuni* and *C. coli* outer membranes.

The present invention provides for tests using monoclonal antibodies to assay for *C. jejuni* and *C. coli* isolated in pure culture and in clinical, food, and water samples.

The present invention also provides immunoassays for the

detection of *Campylobacter* in food, water, and in clinical specimens.

The present invention provides procedures to isolate *C. jejuni* and *C. coli* from foods or other samples and to determine the prevalence of the organisms in the samples.

Because of its high specificity, the monoclonal antibodies may be a useful reagent for the detection of *C. jejuni* and/or *C. coli* in foods, clinical specimens, or *in situ* localization of the bacteria. The antibodies of the present invention may be used further to monitor environmental and/or waste water or various facilities for *C. jejuni* and/or *C. coli* contamination. The testing procedure would include, for example, enzyme-linked immunoassays (ELISAs), immunomagnetic capture, radioimmune assays, biosensor assays and other immunoassays including, but not limited to immunomicroscopy.

The monoclonal antibodies of the present invention may be used singly or in combination, such as in a cocktail mixture, (1) to detect specific *Campylobacter* species, (2) as neutralizing antibodies, or (3) in a composition comprising one or more antibodies to be used in administering passive immunity to humans, livestock, poultry, or other animals.

The antibodies may be used further in side-by-side assays to determine whether the samples react only with the antibodies specific for both *C. jejuni* and *C. coli* or whether they react only with the antibodies that are specific for *C. jejuni* alone.

An immunogen comprising outer membrane complexes from multiple strains of *C. jejuni* may be used as a vaccine which induces high levels of specific antibodies directed against *C. jejuni* and which protects against *C. jejuni* infection in humans, livestock, poultry, or other animals.

An immunogen comprising outer membrane complexes from multiple strains of *C. jejuni* and *C. coli* may be used to as a vaccine which induces high levels of specific antibodies directed against both *C. jejuni* and *C. coli* and which protects against *C. jejuni* and *C. coli* infection in humans, livestock, poultry, or other animals.

The immunogens of the present invention may also be used to

assay the blood of test subjects to determine exposure to *C. jejuni* or *C. coli*.

The scope of the present invention is not limited to the uses discussed above or to the specific examples described below.

Preparation of Immunogen

Campylobacter is a phenotypically diverse organism. This is reflected by the large number of heat stable (Penner LPS system) (Preston and Penner, 1987) and heat sensitive (Lior system) (Suzuki et al., 1993) serotypes that have been identified. Therefore, the type of immunogen is crucial to producing MAbs that recognize an epitope specific to pathogenic Cj strains, and an epitope expressed on all strains of this subspecies.

The immunogen was prepared with outer membrane complexes prepared from strains representative of the most common Cjj and Cc isolated from humans and a Cjj strain isolated from poultry. Outer membrane complexes of ten strains were pooled. These strains represented seven Cjj Penner lipopolysaccharide (LPS) serotype reference strains (O1, O2, O3, O4, O19, O23, O36) (Preston and Penner, 1989; Preston and Penner, 1987), one Cc Penner lipopolysaccharide (LPS) serotype reference strain (O30) (Preston and Penner, 1989; Preston and Penner, 1987), and two strains isolated from a chicken purchased in a local retail market (RM1221 and RM 1222; see below). The LPS reference strains were grown on Brucella Agar with supplements (BA) (Vanderzant and Splittstoesser, 1992). Strains RM 1221 and 1222 were isolated from chicken tissue by a procedure modified from those reported previously (Acuff, 1992). A method was developed to obtain a strain more likely to be adapted to attachment to chicken epidermis. A small "pocket" was formed into a sample of skin cut from the breast of a retail chicken, approximately 1 ml of 1 M NaCl was added to the pocket and drawn in and out of a pipet tip 3 times, and the wash solution was centrifuged at 14,000 rpm for 30 sec. The pellet was resuspended in 200 F1 of Preston Selective Enrichment Broth (PSEB) (Uyttendaele and

Debevere, 19 and added to 10 ml of additional PSEB in a petri dish. The dish was incubated in a jar for 1 day at 42 C under microaerophilic conditions (85% N₂, 10% CO₂, and 5% O₂) with shaking (20-25 rpm). One loopful of the enriched broth was streaked on blood-free *Campylobacter* Charcoal Differential Agar (CCDA) (Acuff, 1992) and incubated for 24 to 48 h under microaerophilic conditions. Two different colony morphologies were noted: strain RM 1221 which grew as a non-isolated "swarming and glistening" colony, typical of the majority of the growth on the plate and most Cjj strains isolated from chicken; and strain RM1222, an isogenic population variant (confirmed by pulsed field gel electrophoresis (PFGE)) which grew as an isolated colony with a "dry" appearance.

Each of the *Campylobacter* strains was subcultured onto approximately 5 to 10 BA plates and grown for 2 days at 42 C in a microaerophilic atmosphere. The bacteria were harvested from plates with sterile plastic loops and suspended in approximately 20 ml of 0.1M Tris - 0.01M EDTA - 0.15M NaCl, pH 8.0 (TEN buffer). The bacteria were vortexed well to suspend the bacteria, then passed through a 26 g needle on a syringe. The bacterial suspension was added to a clean stainless steel Omnimixer jar (Sorvall) and the suspension was mixed with an Omnimixer for 30 sec. The suspension was incubated in a 65 C water bath for 1 hour. The suspension then was mixed with an Omnimixer for 5 minutes on ice (this step shears the bacterial outer membranes from most of the peptidoglycan layer of the bacteria). The suspension was added to a 37.5 ml Oakridge centrifuge tube and centrifuge at approximately 10,000 x g for 20 minutes. The supernatant was transferred to another tube. An amount of TEN buffer equal to the first extraction was added to the pellet, and the pellet was suspended, heated and mixed as described above. The supernatants were pooled and centrifuged again at approximately 10,000 x g to pellet particulates. The supernatant was centrifuged at 50,000 rpm in an ultracentrifuge (Ti70 rotor, Beckman L8) for 2 hours. The supernatant was discarded and the inside of the tube was washed carefully with distilled water without disturbing the pellet. The pellet was

suspended in approximately 2 to 3 ml pyrogen-free (PF)-water (18 megOhm resistance), vortexed vigorously to suspend, and then passed through a 26 g needle to suspend the small clumps of outer membrane more fully. The ultracentrifuge tube containing the suspended outer membrane complex (OMC) was filled with PF-water, and the tube was ultracentrifuged at 50,000 rpm again for 2 hours. The amber-colored pellet was suspended in 1 to 2 ml PF-water.

The presence of protein, lipopolysaccharide (LPS) and lipooligosaccharide (LOS) in the OMC preparation was confirmed by SDS-polyacrylamide gel electrophoresis (both 7.5 and 15%) and Coomassie and protein silver staining, and LPS silver staining. The protein concentration of OMC was determined with a bicinchoninic acid protein assay kit (Pierce, Inc). OMC samples were stored at -20 C until further use.

Immunizations

Each OMC of the ten strains of *Campylobacter* was pooled in an amount resulting in approximately equivalent concentrations of OMC protein for each strain. LOS was present in significant amounts in the OMC as evidenced by silver stains of gel the gel. The mixture was diluted with saline to a final protein concentration of 200 Fg/ml. All immunizations using the OMC mixture were done intravenously and without any adjuvant. The complex of LOS/LPS (mitogenic) with protein in OMC was effective as an adjuvant and in inducing specific antibodies in mice.

BALB/c mice were immunized with three or four intravenous inoculations at approximately 2-week intervals with 50 to 60 Fg of the mixed OMC (first dose of 10 Fg protein; subsequent doses of 20 Fg protein). About 1 week after the 2nd inoculation, antibody production was assessed in an enzyme-linked immunosorbent assay (ELISA) with dilutions of mouse sera (details below).

Preparation of ELISA plates using bacterial cells

An ELISA method was developed for the detection and characterization of anti-*Campylobacter* antibodies with whole

bacterial cells dried on ELISA plates. *Campylobacter* strains were cultured on agar plates, the bacteria were harvested, then suspended in phosphate buffered saline (PBS: 10 mM sodium phosphate, 150 mM NaCl, pH 7.4) to an absorbance of 0.2 at 620 nm. Seventy FL of the suspension was added to polystyrene assay wells (Immulon II, Dynatech, Chantilly, VA or Maxisorp, Nunc, Roskilde, Denmark). The plates were allowed to dry by incubating them for 18 to 24 hours at 37 C, they were washed 3 times with Tris-HCl buffered saline containing 1% Tween 20 (TBS-Tween) or PBS-Tween (diluents), then with a final rinse of PF water. Non-specific binding sites on the wells were blocked by adding 200 Fl of 3% bovine serum albumin in TBS-Tween (BSA-TBS-Tween), then incubating the plate at room temperature (RT) for 1 hr. The plates were rinsed and washed as described above and used immediately, or they were stored in a desiccator at 4 C for later use. Other ELISA plates, blocking buffers and diluents were tested with similar results.

ELISA method to identify anti-*Campylobacter* antibodies in hybridoma supernatants

Samples of culture supernatants containing hybridoma antibody were diluted in TBS-Tween as described above. Samples of 100 Fl were added to immobilized *Campylobacter* in the wells, usually in duplicate, and the wells were incubated with gentle shaking for 1-2 hours at RT. Wells were emptied, then washed and rinsed with water. Bound antibody was detected by adding 100 Fl of alkaline phosphatase (AP)-conjugated rabbit anti-mouse Ig diluted 1:1000 to 1:2000 in ELISA diluent, incubating the wells for 1 hour with shaking, then washing and rinsing the wells with water. Next, 100 Fl of p-nitrophenylphosphate (pNPP) (1 mM pNPP in 10 mM diethanolamine, 0.5 mM MgCl₂, pH 9.5) was added, and the absorbance at 405 nm was determined on a plate reader. Assays were generally read after 30 minutes. In some experiments, screening assays were conducted with horseradish peroxidase-conjugated anti-mouse Ig reagents (Zymed Laboratories), developed using tetramethylbenzimidine-hydrogen peroxide substrate (ELISA Technologies, Lexington, KY), and the

reaction was stopped using 0.3 N HCl.

Cell fusion

Sera from immunized mice were assayed in an ELISA (see method above). Mice producing a high titer of serum antibody against OMC antigen were used for production of MAbs, using a protocol adapted from Oi and Herzenberg (Oi and Herzenberg, 1980). The schedule of immunization is shown in Table 1 below:

Table 1

Day	Procedure	Expt. 1	Expt. 2
0	i.v. inoculation	+	+
13	i.v. inoculation	+	+
29	i.v. inoculation	+	+
32	cell fusion	+	-
36	i.v. inoculation		+
40	cell fusion		+

A mouse producing anti-OMC antibody by ELISA was selected in each of two fusion experiments and inoculated intravenously with the mixed OMC suspension (100 to 200 Fg of protein in PBS) either three (Expt. 1) or four (Expt. 2) days prior to cell fusion 1 or 2, respectively. Equal numbers of immune spleen cells and myeloma cells (P3X63-Ag8.653, Kearney et al., *Journal of Immunology* 123: 1548-1550 (1979)) were fused by treatment with 50% PEG 1450 (American Type Culture Collection, Manassas, VA), and the fusion suspension was dispersed into 96-well tissue culture plates, 200 Fl/well, at a cell density of 1.5×10^6 cells/ml. Hybridomas secreting *Campylobacter*-specific antibody were identified by ELISA (details below).

Initial screening of Hybridoma supernatants

Fusion culture supernatants were harvested after approximately two weeks growth, diluted (1:5 - 1:10) in Tris-

buffered sal (TBS, 25 mM Tris-Cl, 0.5 M NaCl, pH 7.4) containing 10 mg/mL bovine serum albumin (BSA) and 0.05% Tween-20 (BSA-TBS-Tween) (referred to below as diluent), and applied to *Campylobacter*-coated assay wells. Each culture was screened on a panel of wells containing each of 10 different *Campylobacter* strains included in the preparation of the OMC immunogen: (LPS serotypes O1, O2, O3, O4, O19, O23, O30, O36, and isolates RM1221 and RM1222). In these screenings, AP-conjugated rabbit-anti-mouse (IgG + IgM + IgA) (Zymed Laboratories, South San Francisco, CA) was used as labeled reagent and p-nitrophenylphosphate (pNPP) as substrate (1 mM pNPP in 10 mM diethanolamine, 0.5 mM MgCl₂, pH 9.5). Positive cultures were identified (typically absorbance greater than 0.5 absorbance units at 405 nm after 30 minutes), using a microplate reader (V-max, Molecular Devices, Menlo Park, CA). In some screening assays, the phosphate-buffered saline (0.005 M sodium phosphate, 0.15 M NaCl, pH 7.0, PBS) was used instead of TBS in the diluent. Variations in buffer components did not appear to affect the results. In addition, horseradish peroxidase was used as label in most subsequent screenings of clones (see below).

Reproducibility of induction of anti- Cj and anti- Cj /Cc MAbs by immunogen

Approximately 500 wells were screened by ELISA with each of the 10 strains (9 Cjj, 1Cc) used for the OMC immunogen as antigen. Approximately 55% of the Fusion 1 wells (Figure 10, A through D) and 26% of the Fusion 2 wells (Figure 11, A through I) were positive with at least one of the 10 strains. Most of the wells contained antibody that was positive for multiple strains. Between 6 and 8% of the Fusion 1 and Fusion 2 wells were positive for at least 9 of 10 strains. Many wells contained Cj -specific antibody and many were Cj /Cc-specific in initial ELISA screening. The results obtained for two independent fusion experiments indicated that the mixed OMC was a very effective immunogen for inducing consistently MAbs that recognize: (1) different *Campylobacter* outer membrane molecules,

(2) Cj -specific antigens, (3) antigens common to both Cj and Cc, but not other Campylobacters.

Expansion and cloning of hybridomas

Selected cultures were transferred to larger wells as needed and frozen. Selected hybridoma cultures were cloned by limiting dilution. Clones were expanded in culture, permitting harvest of supernatant, freezing of cell lines, and preparation of ascites fluid. Selected lines were recloned in order to improve growth characteristics and to ensure the clonality and stability of cell lines. MAbs were assayed for isotype by ELISA, using isotype-specific antibodies conjugated to horseradish peroxidase (Zymed Laboratories).

Antibody production *in vivo*

BALB/c mice were injected with 2,6,10,14-tetramethylpentadecane (Aldrich Chemical Co., St. Louis, MO) 10 days and 3 days prior to intraperitoneal inoculation with 6×10^6 viable hybridoma cells. High-titer ascitic fluid and sera were obtained from most of the mice within 3 weeks of inoculation. Ascitic fluid was tested for antibody activity by ELISA.

Specificity of MAbs

Ascitic fluids positive by ELISA were characterized further for specificity with additional strains of bacteria in ELISA. Approximately 150 strains of Cj, Cc, non-Cj/Cc *Campylobacter*, Cj subspecies *doylei* (Cjd), *Arcobacter*, *Salmonella*, and other Gram-negative enteric bacteria were assayed by ELISA with 21 ascitic fluids produced from different hybridomas. An additional 130 strains were assayed with C731 (anti-Cj/Cc) and C740 (anti-Cj). Human, chicken, turkey, calf and pig isolates were represented among the Cj and Cc strains. Approximately 60 of the Cj and Cc isolates were isolated from turkeys representing 28 locations in the U.S. and were highly diverse genotypically based on unique pulsed gel electrophoresis patterns (not shown). Among the gram-negative enteric isolates were 14 different serotypes of *Salmonella* spp. and 6 *E. coli*

0157:H7 stra The results shown in Figure 1 are a summary of the data from these experiments.

The results of these initial ELISA assays indicated that MAbs C740 and C760 bind to Cjj and Cjd strains, but not to Cc or any other strain tested. C740 and C760 each bound to 92 of 93 (99%) Cjj strains. C740 and C760 were considered likely to be identical hybridomas based on their identical specificity in ELISA and immunoblots and identical IgG isotypes. Therefore, only C740 was analyzed further. MAbs C731, C736, C775, C777, C779, and C791 bind to most Cj and Cc strains, although some differences in the amount and specificity of binding were noted. MAbs C810, C785, and C751 bind to most, but not all Cj and Cc strains. MAb C753 binds to a few Cj strains, and not to Cc strains. The remainder of the MAbs bind to selected strains of Cj and Cc. MAbs C783 and C735 bind only to the chicken-isolated Cj strains included in the immunogen. The number of isolates recognized by MAbs C731, C740 and C753 is shown in Table 2.

Table 2

Species	No. Strains	Number positive with MAb (%)		
		C731	C740	C753 ^c
Cj	160	160 (100)	159 (99)	54 (58)
Cc	70	70 (100)	0 (0)	0 (0)
Cj subspecies <i>doylei</i>	6	6 (100)	6 (100) ^a	0 (0)
<i>Campylobacter</i> , non- <i>jejuni</i> and - <i>coli</i>	30	0 (0) ^b	0 (0) ^b	0 (0)
<i>Arcobacter</i> spp.	14	0 (0)	0 (0)	0 (0)
<i>Helicobacter</i> <i>pyllorum</i>	3	0 (0)	0 (0)	ND
<i>Salmonella</i> spp.	14	0 (0)	0 (0)	0 (0)
Other Gram neg. enterics	10	0 (0)	0 (0)	0 (0)

a Binding was lower than with most Cj strains.

b Binding was much lower than with Cj or Cc strains: range of OD₄₀₅ values were 0 to 0.15.

c For C753, 96 strains of Cj, 32 strains of Cc, 3 strains of Cj doylei, and 15 strains of non-Cj/Cc were tested. The number of strains of the other species tested was the same.

None of the 21 MAbs selected for further characterization bound to any strain other than Cj or Cc. Strains of Cjd were assayed also to demonstrate if the antibody is specific for both subspecies of Cj. C740 and C731 bound to 6 strains of Cjd; however, binding was ~50% lower relative to other strains of Cjj. This result suggested that the epitope recognized on Cjd strains is: (i) present, but in lower quantity, (ii) present, but sterically hindered, or (iii) structurally similar and cross-reactive, but not identical. Therefore, the OMC immunogen was effective in inducing MAbs that specifically bind to Cjj, Cjd, and Cc.

Antigenic regions recognized by MAbs

Each of the ascitic fluids was tested to determine the OMC antigen recognized by the MAb by SDS PAGE and immunoblot. OMC's were prepared for SDS-PAGE by mixing 1:1 with gel sample buffer and either heating at 100 C for 5 min or not heating. Samples were applied to the gel, the gels were electrophoresed and molecules in the gel were transferred to nitrocellulose in a BioRad SemiDry electroblot apparatus. The nitrocellulose was blocked with a blocking solution (0.5% casein-0.01M Tris-HCl-0.031M NaN₃-0.15M NaCl) for 1 hr or overnight, 4 C. The lanes containing samples were excised and incubated with a 1:500 to 1:1000 dilution (in casein blocking solution) of ascitic fluid and incubated with shaking for at least 2 hr at RT. The membrane was washed with wash buffer (TBS - 0.1% Tween 20 - 0.1% azide, pH 7.4), an alkaline-phosphatase conjugated goat anti-mouse Ig was added (Zymed), the paper was incubated on a shaker for 1 hr at RT, and then the paper was washed. A substrate solution of BCIP/NBT was added and the blot was incubated on a shaker until bands began to appear. When the intensity of staining was sufficient, the substrate was removed

and the paper is washed with water. The approximate Molecular Mass (M_r) of bands binding MAbs were determined by reference to standards included on each blot. In some experiments, 7.5%, 10% and 15% gels were used for OMC samples. Sixteen of the 21 ascitic fluids were also tested for binding to electroblotted molecules from both a heated or non-heated OMC separated on a 7.5% SDS-PAGE gel (Figure 2). Nine or 10 of the MAbs recognized heat-modifiable molecules, presumably proteins. These MAbs bound to the non-heated sample much better than to the heated sample. The heat-modifiability and M_r of the proteins recognized by MAbs C731, C736, C775, C779, C791, and C785 both suggested that these MAbs were specific for the major outer membrane protein (MOMP), or porin, of Cj and Cc (Bolla et al., 1995), a protein comigrating with the porin, or a carbohydrate coupled to the porin. Other MAbs bound to higher or lower M_r proteins.

A summary of the approximate M_r of molecules recognized by the MAbs and their heat-modifiable characteristics are shown in Table 3.

TABLE 3

Ascites	1/Dil	Approx. Mr recognized (kD)	Other
C731	750	35, 45	porin, heat modifiable, Cj/Cc-specific
C735	750	22	not heat modifiable
C736	750	32	porin, heat modifiable
C740	750	35, 43-44	not heat modifiable, Cj-specific
C751	750	60	heat modifiable
C752	750	49	ND
C753	750	35, 45	porin, heat modifiable
C760	750	35, 43-44	same hybridoma line as C740
C762	750	40, 60	heat unstable
C775	750	33, 45	heat modifiable
C777	750	24, 51	not heat modifiable
C779	750	34	heat modifiable
C783	750	43	not heat modifiable
C785	750	41	not heat modifiable
C791	750	32	heat modifiable, porin?
C797	750	68	not heat modifiable
C800	750	40	not heat modifiable
C801	750	45	porin, heat modifiable
C805	750	32	not heat modifiable
C807	750	60	not heat modifiable
C810	750	25	not heat modifiable

M_r are approximate values. Multiple values indicate M_r determined with different percentage gels or multiple bands observed for heated and non-heated samples.

Proteins of M_r between approximately 22 and 68 kD were recognized by the 21 MAbs. The M_r recognized has provided clues to the possible identity of some of the proteins recognized; these will be pursued further in future work. However, the major focus of the initial work has been to characterize anti-Cj and anti-Cj/Cc specific MAbs.

The specificity of an anti-Cj and two anti-Cj/Cc MAbs were examined more fully. Figure 3 shows an SDS-PAGE/immunoblot of the binding of MAbs C731, C740 and C753 to proteins of two Cj strains (RM1049, LPS serotype reference strain O:19, human isolate; and RM 1222, chicken isolate) and a Cc strain (RM1051, LPS serotype reference strain O:30). In this experiment, the incubation time of the development step was extended to reveal

maximum binding of the MAbs. Close examination of the immunoblot revealed that the anti-Cj/Cc MAb, C731, bound to the 45 kD MOMP (porin) (Bolla et al., 1995) of each of the strains (Figure 3). The anti-Cj MAbs C740 and C753, each bound to the porin protein, but they bound more strongly to a diffuse area of the blot of Cj OMC; this is an area at approximately 43-44 kD and lies just below the porin protein. C740 bound much better to the Cj strains than did C753, perhaps reflecting specificity differences observed by ELISA. Coomassie Blue stained predominantly the porin protein. A protein silver stain (BioRad) stained both proteins, but the porin of a Cjj (RM1049) and a Cc (RM1051) strain stained less well than a second Cjj strain (RM1222). Additional SDS-PAGE/immunoblot experiments with heated and non-heated OMC have confirmed that the 45 kD protein recognized by C731 is indeed the porin protein, based on the binding of the MAb to a 35 kD protein (monomer observed predominantly with non-heated porin) and a 45 kD protein (monomer) in heated samples, and an approximately 120 kD protein (porin trimer) in unheated and low SDS (0.01%) samples (Bolla et al., 1995). OMC molecules separated by SDS-PAGE were transferred to ProBlott membrane (Perkin Elmer/ABI) and both the C731-positive region and C740-positive region were N-terminal sequenced in an Applied Biosystems sequencer. Thirteen amino acids at the N-terminal end of the 45 kD protein recognized by MAb C731 were identical to those of a Cjj porin described previously (TPLEEAIKDVS (SEQ ID NO:1), (Bolla et al., 1995)). Thus, C731 recognizes an epitope shared on the porin proteins of both Cjj and Cc strains. The N-terminal sequence of the protein recognized by MAb C740 was XTPLEEAIKDV (SEQ ID NO:2).

A sample of OMC was electrophoresed by SDS-PAGE and transferred to nitrocellulose. The blot was incubated with C740 to identify the protein positive for C740. An adjacent slice of nitrocellulose corresponding to the C740-positive protein was analyzed by matrix-assisted laser desorption time-of-flight mass spectrometry. A heterogeneous series of ions with a peak at approximately 45,800 daltons was observed.

The specificity of MAb C740 for a 43-44 kD protein of Cjj is

demonstrated in Figure 4. SDS-PAGE/immunoblots of OMC of five Cjj strains and 4 Cc strains show that only Cjj proteins bound MAb C740. The MAb bound to a relatively tight band migrating ahead of the porin protein for two of the Cjj strains, and to a more diffuse band for three of the strains. Minimal binding was observed to the four Cc strains (development time in substrate was less than for Figure 4).

Only one of approximately 166 Cj tested have not bound MAb C740 in ELISA. A repeat of the ELISA with the one negative strain indicated that C740 bound, but at 10% the binding to most other Cj strains. In previous experiments, it was noted that C740 binding appeared to correlate with hippuricase activity (Hip) detected by a semi-quantitative assay. (Most *C. jejuni* strains are Hip-positive. *C. coli* strains are Hip-negative. The Hip assay has been used to discriminate between the two species.)

Three Cj strains reported to be Hip-negative (personal communication, John Penner, U. Toronto) were assayed for Hip activity and binding of C740. Two of 3 strains were Hip-negative, or had Hip below the sensitivity of the assay, but did not bind C740. The third strain had relatively average Hip compared to other Cj strains and was positive for C740 by ELISA. However, further analysis of the two Hip-negative strains by a multiplex PCR assay that identifies Cj and Cc (Harmon et al., 1997) indicated that these two strains were not Cj and that the C740 binding specificity was consistent. A cell lysate preparation of the only authentic C740-negative Cj strain was examined in an SDS-PAGE/immunoblot experiment for binding of C740. C740 bound slightly to the porin (similar to that shown above for other strains; Figure 3), but little or no binding was observed to the 43 kD protein. Further work will be required to determine definitively the difference between this strain and C740-positive Cj strains.

Carbohydrate epitopes

It was determined that the porin protein recognized by a number of the MAbs was glycosylated (Figure 5). Cjj OMC (strain RM1222) and Cc OMC molecules (strain RM1051) separated by SDS-

PAGE and blot to nitrocellulose were analyzed for the presence of carbohydrate with the DIG Glycan Stain (Boehringer-Mannheim, according to the manufacturer's instructions) and with 3 lectins specific for sialic acid glycoconjugates [*Limax flavus* Agglutinin (LFA), *Maackia amurensis* Agglutinin (MAA) and Elderberry Bark Lectin (EBL)]. Both the Cjj and Cc porins were stained with the DIG Glycan stain (lanes 4-7 for Cc strain RM1051 and lanes 4-6 for Cjj strain RM1222). The Cc porin stained darker (left panel lanes 4-5, duplicates, RM1051) than the Cjj porin (right panel, lane 4, RM1222), indicating either a greater amount of carbohydrate present and/or differences in the type of sugars present (e.g. sialic acids are more sensitive to staining than other sugars). In addition, lectins that identify sialic acid residues and sialo-conjugates also bound well to the porin protein (lanes 1-3). LPS bands and flagellin protein of the Cc strain stained for carbohydrate as expected (left panel, lanes 4-7, RM1051 OMC; lanes 4-6, RM1222 OMC). The porin proteins of both the Cjj and Cc stained less with the India Ink compared to other proteins (left panel, lane 9), suggesting possible glycosylation. Both the 45 kD and 35 kD monomeric forms of the Cc porin bound C731 (see left panel, lane 8), however the 35 kD monomer was not stained well (left panel, lanes 4-5). These data indicate that the porin proteins of Cc and Cj (Cj less than Cc) were glycosylated.

OMC treated with proteinase K run in SDS-PAGE and electroblotted to nitrocellulose resulted in no binding of MAb C740 to the 43-44 kD protein, nor to any other area of the blot. This demonstrates that the protein is essential for epitope expression or presentation.

IEF/SDS-PAGE 2D gel/immunoblot with anti-Cj MAb C740

A sample of Cjj strain RM1222 OMC was prepared in a sample buffer for extracting outer membrane proteins for 2D gel electrophoresis (Molloy et al., 1998). The sample was run in a 2D gel system (isoelectric focusing first dimension, pH 4-7 range gel; 7.5% SDS-PAGE second dimension), transferred to nitrocellulose and tested for binding of the anti-Cj MAb C740

(Figure 6). Proteins, glycoproteins and other molecules separate by charge in IEF and by relative molecular weight in SDS-PAGE; soluble proteins will appear as spots after silver staining. MAb C740 did not bind to a single protein spot. It bound to a very diffuse area of the blot migrating at greater than 75 kD and less strongly to a series of spots migrating at approximately 43-44 kD. The diffuse area was also stained with the DIG Glycan kit (see paragraph above). These data suggest that a carbohydrate moiety may be associated with the protein recognized by MAb C740, and this association results in a heterogeneous separation of the molecules by IEF. MAb C740 also recognized a series of 43-44 kD monomers that may have different charges and thus different isoelectric points in the IEF gel (Figure 6, see arrow).

Colony blot with anti-Cj MAb C740

Colonies of a Cjj strain growing on agar were transferred to a PVDF membrane, dried, then the membrane was incubated with MAb C740 (Figure 7). Every colony observed (greater than 1000 colonies) bound MAb C740. This result indicates that the epitope recognized on Cjj does not vary phenotypically at a high frequency (less than 0.1%).

Fluorescence microscopy with purified C731 and C740 Mabs

The IgG fractions of MAb C731 and C740 were purified from ascitic fluid. The Ig fraction was precipitated from ascitic fluid with ammonium sulfate. The precipitate was solubilized with 20 mM potassium phosphate buffer pH 8.0 and dialyzed against potassium phosphate buffer. The sample was passed through diethylaminoethyl cellulose equilibrated in potassium phosphate buffer (Whatman, Ltd., Maidstone, U.K.) and the unbound fractions containing protein were pooled. The protein concentration was 1 to 1.5 mg/ml. A sample of purified MAb C740 (anti-Cj) was conjugated with Alexa-488 fluorophore (absorbance maximum 491 nm, emission 515; Molecular Probes, Eugene, Oregon) according to the manufacturers instructions. MAb C731 (anti-Cj/Cc porin) was conjugated with Alexa-546 (absorbance maximum 553 nm, emission 569; Molecular Probes). The two conjugated Mabs were assayed

with both ~~pla~~ bound bacteria and suspended bacteria to examine epitope expression on individual cells (Figure 8).

Figure 8 shows that MAb C731 and MAb C740 bind to most, if not all, of the individual bacteria, but they bind with a subtly different spatial arrangement. C740 appears to bind more closely to the surface of the bacterial cells, whereas C731 (anti-porin) binds further from the surface of the cells. For most cells observed, both MAb-defined proteins were expressed simultaneously. MAbs specific for Cj and Cc specific proteins expressed simultaneously will be advantageous because it will allow development of: (a) of antibody assays using one MAb for capture and another for detection of single organisms, (b) more specific assays, and (c) assays for detecting and discriminating between Cc and Cj.

Fluorescence microscopy of chicken skin with MAb C740

Samples of skin from a processed chicken breast purchased from a retail market were excised, incubated with a dilution of MAb C740 ascites (anti-Cj) and incubated at room temperature for 1 h. The skin was washed with water, added to a solution of fluorescein-conjugated rabbit anti-mouse IgG, incubated for 1h, then the skin was washed again with water. The sample was fixed with a commercial tissue mounting solution and the sample was examined by laser scanning confocal microscopy (Figure 9, magnification approximately 1000X). Single bacteria and clusters of bacteria, presumed to be Cj, were identified by the MAb. Samples incubated with the fluorescent secondary antibody alone were negative. Therefore, the epitope recognized by the anti-Cj MAb C740 appears to be expressed on naturally contaminated samples of chicken.

A recent publication provides some insight into the characteristics of the molecule(s) recognized by C731 (Bacon et al., 1999). A porin-LPS complex was purified from a clinical isolate of Cjj and shown to be cytotoxic for HEp-2, HeLa and Chinese hamster ovary cells. LPS in the complex was detected by a limulus lysate assay, and carbohydrate was detected by Schiff staining and binding of lectins specific for sialic acid,

mannose, and lactosamine (Bacon et al., 1999). The *Galanthus nivalis* agglutinin bound to a carbohydrate that migrates in an SDS-PAGE gel at a very diffuse high M_r region of the gel. These observations regarding the presence of a carbohydrate associated with the porin protein are consistent with our results.

References

Acuff, G. R. (1992). Media, reagents, and stains. In Compendium of Methods for the Microbiological Examination of Foods, C. Vanderzant and D. F. Splitstoesser, eds. (Washington, DC: American Public Health Assoc.), pp. 1093-1208.

Anonymous (1996). Pathogen reduction: hazard analysis and critical control point (HACCP) systems. Final Rule. Federal Register 61, 38806.

Bacon, D. J., Johnson, W. M., and Rodgers, F. G. (1999). Identification and characterisation of a cytotoxic porin-lipopolysaccharide complex from *Campylobacter jejuni*. J Med Microbiol 48, 139-48.

Bolla, J.-M., Loret, E., Zalewski, M., and Pagès, J.-M. (1995). Conformational analysis of the *Campylobacter jejuni* porin. J Bacteriol 177, 4266-4271.

Chaiyaroj, S. C., Sirisereewan, T., Jiamwatanasuk, N., and Sirisinha, S. (1995). Production of monoclonal antibody specific to *Campylobacter jejuni* and its potential in diagnosis of *Campylobacter enteritis*. Asian Pac J Allergy Immunol 13, 55-61.

Docherty, L., Adams, M. R., Patel, P., and McFadden, J. (1996). The magnetic immuno-polymerase chain reaction assay for the detection of *Campylobacter* in milk and poultry. Lett Appl Microbiol 22, 288-92.

Harmon, K. M., Ransom, G. M., and Wesley, I. V. (1997). Differentiation of *Campylobacter jejuni* and *Campylobacter coli* by multiplex polymerase chain reaction. Mol Cell Probes 11, 195-200.

Madden, R. H., Moran, L., and Scates, P. (1998). Frequency of occurrence of *Campylobacter* spp. in red meats and poultry in Northern Ireland and their subsequent subtyping using

polymerase chain reaction-restriction fragment length polymorphism and the random amplified polymorphic DNA method. *Journal of Applied Microbiology* 84, 703-8.

Molloy, M. P., Herbert, B. R., Walsh, B. J., Tyler, M. I., Traini, M., Sanchez, J. C., Hochstrasser, D. F., Williams, K. L., and Gooley, A. A. (1998). Extraction of membrane proteins by differential solubilization for separation using two-dimensional gel electrophoresis. *Electrophoresis* 19, 837-44.

Nachamkin, I., Blaser, M. J., and Tompkins, L. S. (1992). *Campylobacter jejuni* : current status and future trends (Washington, DC: American Society for Microbiology).

Notermans, S., Zwietering, M. H., and Mead, G. C. (1994). The HACCP concept: Identification of potentially hazardous micro-organisms. *Food Microbiology* (London) 11, 203-214.

Oi, V. T., and Herzenberg, L. A. (1980). Selected immunoglobulin-producing hybrid cell lines. In *Methods in Cellular Immunology*, B. B. Mishell and S. M. Shiigi, eds. (San Francisco: W. H. Freeman), pp. 351-372.

Preston, M. A., and Penner, J. L. (1989). Characterization of cross-reacting serotypes of *Campylobacter jejuni*. *Can J Microbiol* 35, 265-273.

Preston, M. A., and Penner, J. L. (1987). Structural and antigenic properties of lipopolysaccharides from serotype reference strains of *Campylobacter jejuni*. *Infect Immun* 55, 1806-1812.

Stanley, K., Cunningham, R., and Jones, K. (1998). Isolation of *Campylobacter jejuni* from groundwater. *J Appl Microbiol* 85, 187-91.

Suzuki, Y., Ishihara, M., Funabashi, M., Suzuki, R., Isomura, S., and Yokochi, T. (1993). Pulsed-field gel electrophoretic analysis of *Campylobacter jejuni* DNA for use in epidemiological studies. *J Infect* 27, 39-42.

Uyttendaele, M., and Debevere, J. (1996). Evaluation of Preston medium for detection of *Campylobacter jejuni* in vitro and in artificially and naturally contaminated poultry products. *Food Microbiol.* 13, 115-122.

Vanderzant, C., and Splittstoesser, D. F. (1992). Compendium of methods for the microbiological examination of foods, 3rd Edition (Washington, DC: American Public Health Association).

Zhou, C., Pivarnik, P., Rand, A. G., and Letcher, S. V. (1998). Acoustic standing-wave enhancement of a fiber-optic *Salmonella* biosensor. *Biosens Bioelectron* 13, 495-500.

Applicant's or agent's file
reference number A70

International application

PCTMS 99/07056

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description
on page 11 and 14, line 19-28 and 21-27

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution
American Type Culture Collection

Address of depositary institution (*including postal code and country*)
10801 University Boulevard
Manassas, Virginia 20110-2209
US

Date of deposit
February 23, 1999

Accession Number
HB-12651; HB-12652

C. ADDITIONAL INDICATIONS (*leave blank if not applicable*) This information is continued on an additional sheet

2 microorganisms are disclosed in the specification. In respect to those designations in which a European Patent is sought, a sample of the deposited microorganism will be made available until the publication or mention of the grant of the European Patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only the issue of such a sample to an expect nominated by the person requesting the sample (Rule 28(4) EPC).

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the International Bureau later (*specify the general nature of the indications e.g. "Accession Number of Deposit"*)

For receiving Office use only

This sheet was received with the international application



Authorized officer

For International Bureau use only

This sheet was received by the International Bureau on:

Authorized officer

We claim:

1. An immunogen comprising outer membrane complex from multiple strains of *C. jejuni* and *C. coli*, said immunogen inducing an immune response in an animal enhancing the production of hybridomas specific for *C. jejuni* and *C. coli* epitopes, wherein said immunogen induces a broad range of antibodies against outer membrane molecules of *C. jejuni* and *C. coli*, but not against other gram-negative enteric bacteria or non-*jejuni/coli* *Campylobacter*.
2. A method of immunizing animals for *C. jejuni* and *C. coli* by:
 - (a) preparing an immunogenic complex according to claim 1 by isolating outer membrane complexes from at least two *Campylobacter* strains selected from the group consisting of *C. jejuni* and *C. coli*;
 - (b) pooling in approximately equivalent concentrations of the *Campylobacter* outer membrane complexes;
 - (c) immunizing animals intravenously; and
 - (d) testing antisera for antibodies against for *C. jejuni* or *C. coli*.
3. A method of making a monoclonal antibody specific for epitopes expressed on the outer membranes of *C. jejuni* and *C. coli*, wherein said monoclonal antibody binds a *C. jejuni* or *C. coli* porin protein or binds a porin protein-carbohydrate complex, the method comprising:
 - (a) preparing an immunogenic complex by isolating outer membrane complexes from at least two *Campylobacter* strains selected from the group consisting of *C. jejuni* and *C. coli*;
 - (b) pooling in approximately equivalent concentrations of the *Campylobacter* outer membrane complexes;
 - (c) immunizing animals intravenously;
 - (d) screening antisera for *Campylobacter* antibody production;
 - (e) fusing isolated spleen cells from animals positive for *Campylobacter* antibody production and myeloma cells;

(f) isolating hybridomas making antibodies that bind *Campylobacter* and

(g) screening and identifying monoclonal antibodies that bind *Campylobacter*.

4. The method of claim 3, wherein the immunogen further comprises *Campylobacter* strains isolated from a 1 M NaCl wash of fresh chicken epidermis.

5. A monoclonal antibody made by the method of claim 3, wherein the antibody binds *Campylobacter jejuni* specifically and does not cross react with other non *C. jejuni* *Campylobacters*.

6. A monoclonal antibody made by the method of claim 3, wherein the antibody binds a common epitope of *C. jejuni* and *C. coli*.

7. A monoclonal antibody made by the method of claim 3, designated as C731, recloned and renamed as C818, and deposited as ATCC HB-12651.

8. A monoclonal antibody made by the method of claim 3, designated as C740, recloned and renamed as C825, and deposited as ATCC HB-12652.

9. A monoclonal antibody specific for epitopes expressed on *C. jejuni* and *C. coli*, wherein said monoclonal antibody binds a *C. jejuni* and *C. coli* porin protein or binds carbohydrate bound to a porin protein, said porin comprising the 45 kD and 35 kD monomeric forms and the trimeric form of the porin.

10. A monoclonal antibody which binds specifically to a 43 kD protein expressed only on *C. jejuni* strains, or binds carbohydrate bound to a 43 kD protein expressed only on *C. jejuni* strains.

11. A method of testing a sample for the presence of *C. jejuni* or *C. coli*, the method comprising the steps of:

(a) exposing a sample suspected of containing *C. jejuni* or *C. coli* to MAb which specifically binds both *C. jejuni* and *C. coli*;

(b) detecting MAb-antigen binding, said binding being indicative of the presence of *C. jejuni* or *C. coli* in said sample; and

(c) capturing *C. jejuni* or *C. coli* with MAb-conjugated-magnetic beads or MAb-conjugated-polystyrene beads or MAb conjugated or bound to a solid matrix, and detecting bound *C. jejuni* or *C. coli* using a method selected from: a second specific MAb, a PCR-specific assay, mass spectrometry (MALDI-TOF), reporter phage specific for *C. jejuni* or *C. coli*, optical sensing, and electronic sensing.

12. The method of claim 11 wherein said sample is selected from the group consisting of poultry, swine and bovine carcasses, tissues and manure; animal production (farm) or processing water and equipment; biofilms on surfaces of animal carcasses, cells, tissues, production equipment or processing equipment; clinical samples; fruit and vegetables; and fruit and vegetable irrigation and processing water.




Figure 1A




Figure 1B




Figure 1C




Figure 1D




Figure 1E




Figure 1F




Figure 2A




Figure 2B




Figure 3




Figure 4




Figure 5B




Figure 5A




Figure 6






Figure 7

7/22



C740 conjugated
with Alexa488



C731 conjugated
with Alexa546

Figure 8A

Figure 8B




Figure 9

9/22

Fusion Plate	COL-UMN	ROW	Clone#	Cj O:1				Cj O:2				Cj O:3				Cj O:4				Cj O:19				Cj O:23				Cc O:30				Cj O:36				Cj RM1221									
				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+									
1	A	1																																											
	1	A	3	+																																									
	1	A	6																																										
	1	A	8																																										
	1	A	9																																										
	1	B	2																																										
	1	B	2																																										
	1	B	2																																										
	1	B	2																																										
	1	B	2																																										
	1	B	2																																										
	1	B	2																																										
	1	B	2																																										
	1	B	2																																										
	1	B	2																																										
	1	B	3																																										
	1	B	7	D	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	1	C	5																																										
	1	C	5	C722	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-							
	1	C	5	C723	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-								
	1	C	5	C764	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-								
	1	D	3	C744	+	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++	++									
	1	E	3																																										

10 / 22

Figure 10A

++=0.3 TO 0.5; ++=0.5 TO 0.8; +++=0.8 TO 1.2; +++++= >1.2														
Fusion Plate	COL- UMN	ROW	Clone#	Cj 0:1	Cj 0:2	Cj 0:3	Cj 0:4	Cj 0:19	Cj 0:23	Cc 0:30	Cj 0:36	Cj 0:39	Cj 1221	Cj 1222
1	E	12		+++	+++	+++	+++	+++	+++	++	+++	+++	+++	+++
1	F	7	DISCAR D	++	++	++	++	++	++	++	++	++	++	++
1	G	4	C742	+	+									+
1	H	9		++	+	+								++
2	A	4		+++	+++	+++	+++	+++	+++		++	++	++	++
2	A	6	DISCAR D	++	+	++	++	++	++	+	++	++	++	++
2	A	12		++	++	++	++	++	++	++	+	++	++	++
2	B	1	DISCAR D	+++	+++	+++	+++	+++	+++	++	++	++	++	++
2	B	4												+
2	C	8			+	++	++				+	+	+	++
2	C	11				++	++	++	++	++	+	++	++	++
2	C	12	DISCAR D						+					++
2	E	1	C701,C 702		++	++				+				++
2	F	12			+	+		+						
2	G	4		+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
2	G	5		++	++	++	++	++	++	+	+	+	+	++
2	G	11			+	++				++	+		+	++
2	G	12	DISCAR D		+	+		+					+	+

Figure 10B

+ = 0.3 TO 0.5; ++ = 0.5 TO 0.8; +++ = 0.8 TO 1.2; ++++ = >1.2													
Fusion Plate	COL-UMN	ROW	Clone#	C 0:1	C 0:2	C 0:3	C 0:4	C 0:19	C 0:23	Cc 0:30	C 036	Cj	Cj
										RM1221	RM1222		
2	H	4			+	+++	+++	+	+			+	++
2	H	5			+	++	++	+	+			+	+
3	A	10			+	+	++					+	+
3	A	12										+	
3	B	3	DISCAR D		+		+		+	+	+	+	++
3	C	7			+		+					+	++
3	C	10			+							+	++
3	D	2			+	+	++		++	+	+	+	+++
3	E	8	C714, C715									++	
4	B	8				+	++						
4	B	10			++	+++	+++	+++	+++	++	+++	+++	
4	B	11				+					+	+	
4	C	9						+++					
4	D	5			++	++	+	+	+	+	++	++	
4	E	6									++	++	
4	F	4							++			++	
4	G	1										+	
5,6,7	A	2										++	+
5,6,7	A	3			++	+++	+++	+++	+++	++	+++	+++	
5,6,7	A	4										++	
5,6,7	B	1										++	

Figure 10C

+=0.3 TO 0.5; ++=0.5 TO 0.8; +++=0.8 TO 1.2; +++++= >1.2						
Fusion Plate	COL- UMN	ROW	Clone#	Cj O:1	Cj O:2	Cj O:3
5,6,7	B	4	DISCAR		+	+
5,6,7	B	5	D			+
5,6,7	C	1		+	+++	+
5,6,7	C	2		+++	+	+++
5,6,7	C	3		++	+++	+++
5,6,7	C	4		++	+++	+++
5,6,7	D	1		+	+++	+++
5,6,7	D	4		+	+++	+++
5,6,7	F	4			+	++
5,6,7	G	1				++

Figure 11A

Fusion Plate	COL- UMN	ROW	Clone#	Cj O:1				Cj O:2				Cj O:3				Cj O:4				Cj O:19				Cj O:23				Cc				Cj O:36				Cj				Cj RM1222											
				++=0.3 TO 0.5;	++=0.5 TO 0.8;	+++=0.8 TO 1.2;	++++= >1.2	++=0.3 TO 0.5;	++=0.5 TO 0.8;	+++=0.8 TO 1.2;	++++= >1.2	++=0.3 TO 0.5;	++=0.5 TO 0.8;	+++=0.8 TO 1.2;	++++= >1.2	++=0.3 TO 0.5;	++=0.5 TO 0.8;	+++=0.8 TO 1.2;	++++= >1.2	++=0.3 TO 0.5;	++=0.5 TO 0.8;	+++=0.8 TO 1.2;	++++= >1.2	++=0.3 TO 0.5;	++=0.5 TO 0.8;	+++=0.8 TO 1.2;	++++= >1.2	++=0.3 TO 0.5;	++=0.5 TO 0.8;	+++=0.8 TO 1.2;	++++= >1.2	++=0.3 TO 0.5;	++=0.5 TO 0.8;	+++=0.8 TO 1.2;	++++= >1.2	++=0.3 TO 0.5;	++=0.5 TO 0.8;	+++=0.8 TO 1.2;	++++= >1.2												
2	B	2		+	+	+	+		+	+	+		+	+	+		+	+	+		+	+	+		+	+	+		+	+	+		+	+	+		++	++	++	++											
2	B	5																																																	
2	B	8		+	++				+	++																																									
2	B	10																																																	
2	B	11		+																																															
2	C	4		+	++	++																																													
2	C	6		+																																															
2	C	9							+																																										
2	D	6		++	++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++	++	++	++	
2	E	6		+	++					++																																									
2	E	8		+																																															
2	F	3		++	++	++	++			++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++		++	++	++	++	++	++
2	F	4				+																																													
2	F	9							+		++																																								
2	G	5							++																																										
2	G	7							++		++																																								
2	G	12								++	++																																								
2	H	10							++		++																																								
3	A	1								++	++																																								
3	A	2																																																	
3	A	9																																																	
3	A	12																																																	
3	B	6																																																	

+=0.3 TO 0.5; ++=0.5 TO 0.8; +++=0.8 TO 1.2; ++++>1.2														
Fusion	COL-Plate	UMN	ROW	Clone#	Cj O:1	Cj O:2	Cj O:3	Cj O:4	Cj O:19	Cj O:23	Cc O:30	Cj O:36	Cj RM1221	Cj RM1222
3	C	1							+++			+		
3	D	11			++				++			+++	+++	
3	E	4			+	++		++	+			+++	++	
3	E	9			++	+			+			+	++	
3	E	12			++	++		+	++			+++	+++	
3	F	10			++	+		+				+++	++	
3	G	7			++			++		+		+++	+++	
3	H	10												
4	A	6			+	+		++			++	+++	+++	
4	A	8										++	++	
4	B	4										+	+	
4	B	12						++				++	+	
4	C	10										+	+	
4	D	2			++							++	++	
4	D	6						++						
4	D	7						+					+	
4	E	1			+	++		++	+=		++	+++	+++	
4	E	10			++	++		++	++		++	+++	+++	
4	G	2			+	+		++			++	+++	+++	
4	G	8			++	++		++	++		++	+++	+++	
4	H	6			+			++				++	++	
5	A	3			+	++		+	++		++	++	++	
5	A	4			+			+			+	+	+	

+ = 0.3 TO 0.5; ++ = 0.5 TO 0.8; +++ = 0.8 TO 1.2; ++++ = >1.2													
Fusion Plate	COL-UMN	ROW	Clone#	Cj 0:1	Cj 0:2	Cj 0:3	Cj 0:4	Cj 0:19	Cj 0:23	0:30	Cj 036	Cj 1221	Cj 1222
5	A	6		+	++	+	++	+++	++			+	+++
5	A	11		+++	+++	++	++	+++	++			+++	+++
5	B	4			++	++	++		++			++	++
5	B	11			++	++	++		+				
5	C	3								+			
5	C	9											
5	C	12			+	+	++	+	+			++	++
5	D	3		+	+	+	++	+	+			++	++
5	D	10		++	++	++	++	++	+			++	++
5	D	11			++	++	++					++	++
5	E	4		+	++	++	++	++	++			++	++
5	E	11		++	++	++	++	++	++			++	++
5	F	9				++			++			++	++
5	F	11			++	++	++	++	++			++	++
5	G	6										+	++
5	G	7							++			++	++
5	G	10										+	+
5	G	12										++	++
5	H	4				+	+		++			++	++
5	H	5					+					+	++
6	A	3				++			+			++	+
6	A	4							+			+	+
6	B	1				++			+			++	++

Figure 11D

+=0.3 TO 0.5; ++=0.5 TO 0.8; +++=0.8 TO 1.2; ++++ = >1.2													
Fusion Plate	COL-UMN	ROW	Clone#	Cj 0:1	Cj 0:2	Cj 0:3	Cj 0:4	Cj 0:19	Cj 0:23	Cc 0:30	Cj 0:36	Cj 10221	Cj 10222
6	B	2		++	+	+	++			++	++	++	+
6	B	4								++			
6	B	5			+					+++	+++	+++	++
6	B	6											++
6	B	7		+++	++	++	++			++	+++	+++	+++
6	B	9		+++	+++	+++	+++	++	++	++	++	++	+++
6	B	12			+			+					+
6	C	3		+++	+++	+++	+++	++	++	++	++	++	++
6	C	7			+					+			++
6	D	5		+++	+++	++	++			++	++	++	+++
6	D	7		+	+	+++	++	+	+	++	++	++	+++
6	E	1		++	++	+	++			++	++	++	++
6	E	5		++	++	++	++			++	++	++	++
6	E	7		+	++	+	++			+	++	++	++
6	E	9			+		++	+		++	++	+	++
6	F	1			+				+		+		+
6	F	3		+++		+++	++	++	++		++	++	++
6	F	5			++								++
6	F	6			+		++	++		++	+	+	++
6	F	9											
6	F	10											
6	G	2		++	++	++	++			++	++	++	++
6	G	11			++	++	++						

Figure 11E

+=0.3 TO 0.5; ++=0.5 TO 0.8; +++=0.8 TO 1.2; ++++= >1.2													
Fusion Plate	COL- UMN	ROW	Clone#	CJ 0:1	CJ 0:2	CJ 0:3	CJ 0:4	CJ 0:19	CJ 0:23	Cc 0:30	Cc 0:36	Cj 12:21	Cj 12:22
7	A	5										+	+++
7	A	9										+	++
7	A	11								++		+	+
7	B	1		+++	+++		+++					+	+++
7	B	2		++	++	++	++					++	+++
7	B	7		++	++			++	++			++	+++
7	B	8		+++	+++	+++	+++	+++				+++	+++
7	C	2				++	++			++		+++	+++
7	C	3		++	+++	++			+++	+++		++	+++
7	C	4		++	+++	+++	+++	+++	+++	+++		+++	+++
7	C	5			++	++	++	++	++	++		++	+++
7	C	6		+++	+++	+++	+++	+++	+++	+++		+++	+++
7	C	7		++	+++	+++	+++	+++	+++	+++		+++	+++
7	C	9		++	+++	+++	+++	+++	+++	+++		+++	+++
7	C	10		+++	+++	+++	+++	+++	+++	+++		+++	+++
7	C	11		+++	+++	+++	+++	+++	+++	+++		++	++
7	D	1				+	++	++	++	++		++	++
7	D	8		+++			+++	+++	+++	+++		+++	+++
7	D	9		++	++	++	++	++	++	++		++	++
7	D	12								++		++	++
7	E	1				++	++	++	++	++		++	++
7	E	2				++	++	++	++	++		++	++
7	E	3				++	++	++	++	++		++	++

+=0.3 TO 0.5; ++=0.5 TO 0.8; +++=0.8 TO 1.2; ++++ = >1.2													
Fusion Plate	COL- UMN	ROW	Clone#	Cj O:1	Cj O:2	Cj O:3	Cj O:4	Cj O:19	Cj O:23	Cc O:30	Cj O:36	Cj RM1221	Cj RM1222
7	E	4		+++	+++	++	+	+++	+++		++	+++	
7	E	6						++	++		+	++	
7	E	7		++	++			+++	+++	++	++	+++	
7	E	8						++	++		++	++	
7	E	9			++			++	++		++	++	
7	E	10			++			++	++		++	++	
7	F	2			++								
7	F	3			+							++	
7	F	5			++	++							
7	F	6		++	++	++	++	++	++	++	++	++	
7	F	7		+	++	++	++	++	++	++	++	++	
7	F	8			++			++	++	++	++	++	
7	F	11		++				++	++	++	++	++	
7	G	1			++		++	++	++	+	++	++	
7	G	5					+++						
7	G	7				++					+	+	
7	G	8			++	++							
7	G	12				++		++	++				
7	H	4				+		++	++			++	
7	H	6			++	+++	+++	+++	+++	++	++	++	
7	H	8						++	++	++	++	++	
7	H	9			++	++	++	++	++	++	++	++	
7	H	12				++		++	++	++	++	++	

Figure 11G

Fusion Plate	COL- UMN	ROW	Clone#	+=0.3 TO 0.5; ++=0.5 TO 0.8; +++=0.8 TO 1.2; ++++= >1.2				Cc 0:30	Cj 0:36	Cj RM1221	Cj RM1222
				Cj O:1	Cj O:2	Cj O:3	Cj O:4				
8	A	9					+++				
8	A	12			+++					+++	+++
8	B	1								+++	++
8	B	2			+++					+	+++
8	B	4			++					++	++
8	B	7			++	++				++	++
8	B	8			++					++	+
8	B	10			++	++				++	++
8	C	6			+	+++				++	++
8	C	7			++					++	++
8	C	10					+++			++	++
8	D	1			+	+++		++	++	++	+++
8	D	7			++	++	++	++		+++	++
8	D	11			+	+++	++			++	+++
8	E	3				++		+++			
8	E	4						+++			
8	E	6			+++	+++	+++	+++	++	+++	+++
8	E	8				++					
8	E	10			+	+++				++	++
8	E	11			+	+++	++			++	++
8	E	12				++				1++	++
8	F	1			+	+++			++	++	++
8	F	3			++				++	++	+

+=0.3 TO 0.5; ++=0.5 TO 0.8; +++=0.8 TO 1.2; ++++ = >1.2									
Fusion Plate	COL- UMN	ROW	Clone#	Cj 0:1	Cj 0:2	Cj 0:3	Cj 0:4	Cj 0:19	Cj 0:23
8	F	10		+++					
8	G	1		+	+++	++	++	++	++
8	G	2			++				
8	G	6				+++		++	+++
8	H	2		+++	+++			+	++
8	H	6		+++	+++	+++	+++	+++	+++
8	H	7			+++			++	++
8	H	10			+++			++	++
8	H	11			+++			++	++

22/22

Figure 111

SEQUENCE LISTING

<110> Mandrell, Da E.

Bates, Anna H.

Brandon, David L.

<120> Monoclonal Antibodies Against *Campylobacter jejuni* and
Campylobacter coli Outer Membrane Antigens

<130> 029497 seq

<140> Docket No. 0294.97

<141> 1999-03-25

<150> 60/080,166

<151> 1998-03-31

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 13

<212> PRT

<213> *C. jejuni* and *C. coli*

<400> 1

Thr Pro Leu Glu Glu Ala Ile Lys Asp Val Asp Val Ser

1 5 10

<210> 2

<211> 11

<212> PRT

<213> *Campylobacter jejuni*

<400> 2

Xaa Thr Pro Leu Glu Glu Ala Ile Lys Asp Val

1 5 10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/07056

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) A61K 39/00, 39/116, 39/02; C07K 16/00; G01N 33/53, 33/554
US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/184.1, 203.1, 234.1; 530/ 388.1, 388.2; 435/ 7.2, 7.32, 7.7, 7.92

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, MEDLINE, EMBASE, CAB
search terms: campylobacter, c(lw)jejuni, c(lw) coli, antibod?, outer membrane?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,470,958 A (BLASER et al.) 28 November 1995, see entire document.	1, 2, ---
-		3-6, 11, 12 ---
Y		7-10
-		---
A		---
X	US 5,200,344 A (BLASER et al.) 06 April 1993, see entire document.	1, 2 ---
-		3-6, 11, 12 ---
Y		7-10
-		---
A		---

 Further documents are listed in the continuation of Box C. See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance		
"E" earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

23 MAY 1999

Date of mailing of the international search report

02 JUN 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

J. Lawrence Jr.
JENNIFER GRASER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/07056

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/184.1, 203.1, 234.1; 530/ 388.1, 388.2; 435/ 7.2, 7.32, 7.7, 7.92

